INTRODUCTION
PGE 2 biosynthesis pathway is strongly implicated in wide-ranging physiological and pathological events, such as ovulation, implantation and parturition during reproduction; ductus arteriosus closure in neonates; pain hypersensitivity, inflammation, febrile response, gastric mucosal protection, T cell differentiation and repair during acute or chronic injury; cell proliferation, neoplastic transformation and invasion during carcinogenesis as well as alteration in kidney function, vascular tone, bone resorption and neurological disorders like Alzheimer's disease. Therefore expanding our understanding of regulation of the PGE 2 biosynthesis has unique biochemical and cellular relevance. [1] The regulation of PGE2 synthesis pathway can be divided into three main steps, in which a key step involves the mobilization of arachidonic acid from membrane phospholipids by the action of phospholipase enzymes. [2] [3] [4] [5] Among many phospholipases, the cytosolic phospholipase A2-alpha (cPLA2α) has very high substrate specificity towards arachidonic acid, and therefore is the key regulator of intracellular arachidonic acid release. [2] [3] [4] [5] [6] The mobilization of arachidonic acid is generally considered the rate limiting step in the synthesis of PGE2 . [4] The subsequent steps in the PGE 2 synthesis pathway involve the alignment of COX-2 and microsomal PGE2 synthase (mPGES), which convert intracellular arachidonic acid to a prostaglandin intermediate and finally PGE2. [7] [8] [9] The intracellular release of arachidonic acid which occurs via cPLA2α favors COX-2 and mPGES to synthesize PGE2 instead of other prostaglandins. [8] [9] [10] Moreover, cPLA2α mediated arachidonic acid release is also known to increase COX-2 promoter activity, as well as protein synthesis, thereby redirecting arachidonic acid toward PGE2 synthesis. [11] Altogether, the overall process of PGE 2 synthesis is highly complex and remains to be further investigated at the transcriptional level.
In the past decade, cyclooxygenase, particularly COX-2, has received significant attention for their importance in prostaglandin biosynthesis. Several elegant reports have provided evidence that COX-2 inhibition and consequent down-regulation of PGE2 synthesis have important therapeutic implications in many pathological conditions, such as inflammation and carcinogenesis. [12] [13] [14] [15] However, in recent investigations, it has been recognized that long-term COX-2 inhibition is not safe due to increased cardiac and cerebrovascular side effects. [16] [17] [18] The explanation for such complications in the setting of COX-2 inhibition is an ongoing production of arachidonic acid by phospholipase A2. This arachidonic acid is then utilized by competing homeostatic pathways, which results in the relative change of certain eicosanoid levels, to cause these side effects. [19] [20] [21] [22] Similar to COX-2, the importance of cPLA2α has been confirmed in vivo via genetic experiments that show a reduction in levels of PGE2 and polyposis in APC min/+ with either mutation in or deletion of the cPLA2α locus. [23, 24] In stark contrast to COX-2 antagonists, the inhibition of cPLA2α decreases the overall production of arachidonic acid, thereby preventing the misdirection of PGE2 substrate to competing homeostatic pathways that cause cerebrovascular toxicity. In fact, transient middle cerebral artery occlusion in cPLA2α -/-mice results in smaller infarcts, and these mice develop less neurological deficit. [5] Therefore, cPLA2α is a remarkable alternative candidate node instead of COX-2 inhibition to target the PGE2 synthesis pathway and thereby expand our basic understanding of prostaglandin biosynthesis that is central to cellular homeostasis and the pathobiology of many diseases.
KLF proteins have elicited significant attention due to their emerging key regulatory roles in several cellular functions.[25-32] Our laboratory has been studying the role of KLF proteins, in particular KLF11 and KLF13, in both lipid and glucose metabolism. [33] [34] [35] In the current study, we performed extensive characterization of the role of KLF11 as a key mediator of prostaglandin biosynthesis and report that the expression of KLF11 reduces PGE2 levels. Mechanistically, we find that KLF11 performs these functions by binding to distinct sites in the cPLA2α promoter and recruiting chromatin silencer complexes. Interestingly, this effect can be blocked by the EGFR-AKT-mediated phosphorylation of T56, a key regulatory residue within the KLF11-R1domain also known as Sin3a interacting domain (SID). Therefore, to our knowledge, the current study clearly outlines for the first time the role of any KLF protein in the downregulation of cPLA2α and a consequent decrease in PGE2 synthesis as well as the role of AKT in the transcriptional regulation of cPLA2α. The biological importance of these novel biochemical pathways, through the downregulation of PGE2 synthesis, may very likely have a pleiotropic impact on important cellular functions.
provided by Dr. Mark Cowan (U of Maryland, Baltimore, MD). Promoter reporter deletion constructs of cPLA2α were cloned into the SacI and NheI sites of the pGL2 luciferase reporter vector (Promega) and verified by sequencing at the Mayo Clinic Molecular Biology Core Facility. Using the cPLA2α promoter reporter construct containing sequence from -300 to +150 base pairs, the GC-rich site ggagaccagcccacatt ttagcccctcctactc was mutated to ggagaccagttca cattttagcccctcctactc (core SDM1) or ggagac cagcccacattttagcttctcctactc (core SDM2) via the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as recommended by the manufacturer.
Unless specified, for all transfection experiments, 50-60% confluent cells in six-well plates were treated with 1 ml of Opti-MEM (Invitrogen) containing 12 μl of LipofectAMINE (Invitrogen) and 1.2 μg of total DNA. 48 hours later, luciferase activity was measured after normalization. [40, 41] The cPLA2α mRNA expression was examined using semi-quantitative PCR (primer sequence and PCR conditions are outlined in supplemental file A) and cPLA2α enzyme activity was assessed using cPLA2 assay kit (Cayman Chemical, Ann Arbor, MI) KLF11 Plasmids and recombinant adenovirusStandard molecular biology techniques were used to clone full length KLF11, as well as KLF11 deletions containing isolated R1 (amino acids 24-41) or R2 (amino acids 151-162 ) or R3 (amino acids 273-351) fused to the C-terminal domain containing zinc fingers into pcDNA3.1/His (Invitrogen, Carlsbad, CA) as previously described. [40, 41] Using full length KLF11 in pcDNA3.1/His as a template, an extensive library of KLF11 constructs were generated to mutate serine and threonine phosphorylation sites to a non-phosphorylatable alanine or a phosphomimetic aspartic acid, using the QuikChange site-directed mutagenesis kit (Stratagene). A KLF11 mutant ΔE29P-ΔA30P was also generated to examine the role of corepressor Sin3a in the regulation of cPLA2α promoter activity by KLF11. [41] All constructs were verified by sequencing. KLF11 (Ad5CMV.TIEG2) or empty vector (Ad5CMV) carrying recombinant adenovirus were generated in collaboration with the Gene Transfer Vector Core at the University of Iowa.
Purification of phospho-specific T56 KLF11 antibody by affinity chromatography-A 12-mer KLF11 peptide spanning P-Threonine 56 was synthesized, HPLC-purified and conjugated to KLH by the Mayo Clinic Protein Core. Two rabbits were immunized with the peptide by Cocalico Biologicals (Reamstown, PA). The anti-serum was affinity purified against the original phospho-peptide using the EZ™ Sulfhydryl Reactive Antibody Production and Purification Kit according to the manufacturer's protocol (Pierce Biotechnology, Rockford, IL).
Prostaglandin E2 (PGE2) Assay-PGE2 production was measured in the supernatants of cell cultures using an enzyme immune assay kit (Cayman Chemical, Ann Arbor, Michigan) as previously described.[28,36] PGE2 levels were corrected for total protein measurements.
Co-transfection, immunoprecipitation and
Western Blot Analysis-FLO cells (90% confluent in 6-well plates) were co-transfected with His-tagged KLF11 along with siRNA against AKT (AKT1, 2 and 3, ONTARGETplus SMARTpool siRNA, Dharmacon) or scrambled siRNA using LipofectAMINE-2000 (Invitrogen). Each well received 0.6 µg of DNA, 200 pmol of siRNA, 4 µl of LipofectAMINE-2000 and 2250 µl of Opti-MEM I (Invitrogen). 48 hrs later, cell lysate was precleared with Protein A/G agarose bead slurry (Pierce) for 10 minutes at 4 °C. Immunoprecipitations were performed using Omni-probe D-8 antibody (Santa Cruz) overnight at 4 °C. The immunocomplexes were collected by incubating with Protein A/G-agarose beads for 1 hr at 4 °C followed by centrifugation and washing five times with lysis buffer. Western blot analysis was performed as described above using Omniprobe D-8 and anti-phosphoT56-KLF11 antibodies.
NY) was performed as previously described. [42] PCR products were examined on a 2% agarose gel for enrichment of cPLA2α promoter in KLF11 transfected cells compared to controls cells using following primers (Forward 5' to 3' caatcttggctcactgcaagctct and reverse 5' to 3' tcacgcctgtaatcccagcacttt).
Gel Shift Assays-To generate GST fusion KLF11-zinc finger protein, BL21 bacteria were induced with isopropyl-1-thio--D-galactopyranoside and recombinant fusion proteins were then purified using GST-Sepharose beads (Amersham Pharmacia Biotech) as previously described. [41] Gel shift assay was performed using DIG gel shift kit (second generation) as per manufacturers' directions. EGFR-AKT Plasmids and pharmacological inhibitors-Constitutively active and dominant negative AKT constructs were kindly provided by Sushoven Guha (MDACC, Houston TX). Standard molecular biology techniques were used to clone vErbB into the pcDNA3.1/His (Invitrogen) as previously described. [43] All constructs were verified by sequencing. The following inhibitors were purchased from EMD Chemicals, Inc. (Gibbstown, NJ) and used in the concentrations listed: 10 μM PD168393 (EGFR blocker), 100 μM LY294002 (PI3K inhibitor) and 1 μM KP372-1 (AKT inhibitor).
Whole Cell Extracts and
Statistical Analysis-Results are expressed as means with standard error of means (SEM). Each experiment was repeated in triplicates at least three times. An overall F-test of treatment mean equality and Bonferroni method of multiple comparisons (t tests) were used. Statistical analysis was performed using SAS software (version 6.12; SAS Institute, Cary, NC). All statistical tests were two-sided.
RESULTS
KLF11 represses the rate-limiting enzyme, cPLA2α and down-regulates PGE2 synthesis As mentioned, cPLA2α is a rate-limiting enzyme involved in the regulation of PGE2 synthesis [3, 11, 44, 45] and since PGE2 plays a direct role in important biochemical processes and pathological states [13,15, , FIGURE 1B) . Importantly, this KLF11-mediated inhibition of cPLA2α promoter activity was associated with decreased cPLA2α mRNA expression in all three cell lines (FIGURE 1C). Congruent with this data, there was a 34% reduction in cPLA2α enzyme activity in FLO cells infected with the KLF11 adenovirus (474±13 vs 319±2.4 KLF11 Adv, compared to empty Adv controls p<0.05). Similarly, a down-regulation of cPLA2α enzyme activity was confirmed in KLF11-infected SEG-1 as well as SKGT-4 cells (FIGURE 1D) . Furthermore, KLF11 adenoviral infection of FLO, SEG-1 and SKGT-4 cells led to a 45 to 81% reduction in PGE2 production, the final catalytic product of cPLA2α enzyme activity (FIGURE 1E).
Collectively, these results demonstrate that KLF11 represses both cPLA2α promoter and by guest on November 19, 2017 http://www.jbc.org/ Downloaded from enzyme activity while it decreases PGE2 production.
KLF11-mediated down-regulation of cPLA2α-PGE2 inhibits cell proliferation
The experiments thus far described, demonstrate that KLF11 down-regulates cPLA2α-PGE2, though it does not indicate whether these changes impact on any cell function expected from this pathway. Thus, to test the premise that KLF11-mediated down-regulation of the cPLA2α-PGE2 pathway has any biological implications, we took a step wise approach to examine its effects on cell proliferation. We first treated epithelial cells with either cPLA2α inhibitor or the catalytic products of cPLA2α, namely arachidonic acid or PGE2 to examine the relevance of cPLA2α -PGE2 pathway to the cell biological process of proliferation. Next, we overexpressed KLF11 using AdvKLF11 infection of cells to assess if KLF11 can regulate the cell proliferation. Finally, we examined if the catalytic products of cPLA2α abrogates the effect of KLF11 on cell proliferation.
First, to test the effects of the cPLA2α-PGE2 pathway on cellular proliferation, epithelial cells (BE-HGD, FLO and SKGT-4) were treated with either the catalytic product of cPLA2α (30 μM arachidonic acid) or an inhibitor of cPLA2α (40μM AACOCF3α). In FLO cells, compared to control, arachidonic acid increased proliferation by 22±2.6% (p<0.05). In contrast, AACOCF3α decreased cell proliferation by 39.5±0.4% (p<0.05) (FIGURE 2A). Interestingly, in the presence of either arachidonic acid (PGE2 substrate), or PGE2 (final catalytic product of cPLA2α), the inhibitor of the cPLA2α enzyme failed to decrease cell proliferation. Therefore, this evidence supports the idea that the effects of cPLA2α on cell proliferation are mediated via arachidonic acid release and PGE2 production. Since KLF11 not only represses the cPLA2α promoter but also decreases PGE2 production, it is likely that the growth-regulatory function of this transcription factor is mediated via the cPLA2α-PGE2 pathway under these circumstances.
Consequently, we measured proliferation of epithelial cells (naturally expressing low KLF11 levels) that were transduced with KLF11, and treated for 48 hours with vehicle, 30 μM arachidonic acid, or 2 ng/ml of PGE2. Under these conditions, infection with KLF11 decreased the BrdU positive cells by up to 50% in vehicle treated cells. This antiproliferative effect of KLF11 was completely abrogated in cells treated with either arachidonic acid or PGE2 (FIGURE 2B-D). Therefore, these results demonstrate that the antiproliferative effect of KLF11 is indeed mediated via the down-regulation of cPLA2α-PGE2 pathway in epithelial cells.
Silencing of cPLA2α requires defined KLF11-mediated promoter site recognition and chromatin remodeling To better understand the molecular mechanisms involved in regulation of the cPLA2α promoter by KLF11, we used an extensive battery of approaches, including bioinformatics, deletions and site-directed mutagenesis, as well as EMSA and ChIP assay. For these experiments, to map the KLF binding sites within the cPLA2α promoter, we co-transfected KLF11 with either wild-type core cPLA2α promoter reporter (cPLA2α-wt from -300 to +150 relative to its TSS, which behaves similar to 1200bp fragment in its responsiveness to KLF11-dependent repression) or the same construct carrying CC to TT mutations at one of the two GC-rich sites, referred here as SDM1 or SDM2 (FIGURE 3A). Interestingly, KLF11 is unable to repress the cPLA2α promoter mutated at the distal GC-rich SDM2 site (cPLA2α-wt 36.2±17% vs. SDM2 80.8±20.9% p<0.05, FIGURE 3B). Mutation of the proximal GCrich SDM1 site did not significantly alter KLF11-dependent repression (cPLA2α-wt 36.2±17% vs. SDM1 52±14.7% p>0.05, FIGURE 3B). Binding of KLF11 to these sites was determined by EMSA assays. These experiments revealed that binding of KLF11 to the cPLA2α promoter was completely disrupted with SDM2 mutation, which is required for promoter silencing via KLF11 (FIGURE 3C). To address whether KLF11 binds to the endogenous cPLA2α promoter, we used chromatin immunoprecipitation assays. The results of these experiments demonstrate that the cPLA2α promoter can be occupied in vivo following over-expression of KLF11 (FIGURE 3D). Together, these mechanistic findings demonstrate that, at the cis-regulatory level, KLF11 binds to and represses the cPLA2α promoter via a distinct GC-rich site. Furthermore, KLF11 not only occupies the cPLA2α promoter in vivo but it also behaves as a bona fide repressor of this gene.
Recent investigations have demonstrated that KLF11 functions with multiple chromatin remodelers that bind independently to its repressor domain R1, R2, R3, and the zinc fingers. [40, 41] In addition, each KLF11 domain appears to function via different chromatin remodeling machine.
Therefore, we investigated which mechanisms KLF11 employs for repression of the cPLA2α promoter. Consequently, in an unbiased approach, we initially investigated which of these functional domains, known to bind to different chromatin remodeling machines, are necessary for the regulation of cPLA2α. We used several KLF11 constructs including full length KLF11, as well as KLF11 deletions containing its individual chromatin-binding regulatory domains fused to the C-terminal domain containing zinc fingers (R1-ZF, R2-ZF and R3-ZF) (FIGURE 4A, upper panel). Co-transfection of FLO cells with the cPLA2α promoter reporter construct and these various constructs revealed that compared to empty vector control, R1-ZF repressed cPLA2α promoter activity by 42.4±9.8%, a value not statistically different from the repression exerted by full length KLF11 protein (65.6±12% p>0.05). In contrast, the R2-ZF and R3-ZF failed to repress cPLA2α promoter activity (FIGURE 4A, lower panel and FIGURE 4B). These findings illustrate that the KLF11 R1 domain is functionally important and sufficient in the regulation of the cPLA2α promoter. From our results, we also conclude that the chromatin remodeling machines bound by KLF11 via the R2, R3, and zinc finger domain are unlikely to be involved in this process. Since the R1 domain contains sequences that mediate the interaction with the chromatin corepressor complex, Sin3-HDAC [40, 41] , this information led us to experimentally confirm whether this corepressor system is directly involved in this repression effect. We the compared the regulatory potential of KLF11 construct that carries a mutation which interferes with Sin3a binding to KLF11 (ΔE29PΔA30P-KLF11). [41] As shown in FIGURE 4C, this mutation abolished cPLA2α repression by KLF11. Based upon these findings, we speculated that the E29P-A30P mutation in the R1 domain of KLF11 interferes with Sin3-HDAC recruitment by KLF11 and therefore, KLF11 is not able to repress the cPLA2α promoter. To test this idea, we infected FLO as well as SEG-1 cells with adenovirus carrying a control empty parental vector, wild type KLF11, or KLF11 with the ΔE29PΔA30P mutation. As shown in FIGURE 4D, ChIP assays with an anti-Sin3a antibody demonstrate that while Sin3a occupies the cPLA2α promoter in cells infected with wild type KLF11, the recruitment of this corepressor was abrogated by the ΔE29PΔA30P KLF11 mutant. Together, these findings led us to conclude that the R1 domain is critical in the repression of the cPLA2α promoter and this phenomenon depends upon the binding and function of the Sin3a-HDAC complex. Furthermore, contrary to repression by histone methylation (e.g. polycomb) which is long lived [51, 52] , histone acetylation by Sin3a/HDAC is meant to be short live and susceptible to antagonism by signaling. [53] [54] [55] Therefore, in the following paragraph we describe experiments that explore the idea of a more dynamic regulation of cPLA2α by signaling pathways that could potentially affect KLF function.
Membrane-to-nucleus signaling-dependent Posttranslational changes in KLF11 can modulate KLF1-dependent cPLA2α regulation
To gain more robust biochemical insight into the KLF11 mediated cPLA2α repression, we used an unbiased molecular screening to search and define potential post-translational modifications in KLF11 that could be a target of conspicuous signaling cascades. Guided by bioinformatics-based analyses (Material and Methods), we performed extensive mutagenesis to replace the serines and threonines that were candidates for modification by intracellular signaling kinases with either an alanine (non-phosphorylatable mutation) or aspartic acid (phosphomimetic mutation). The functional impact of these mutations on the ability of KLF11 to repress the cPLA2α promoter was examined (FIGURE 5A). This screening demonstrates that the KLF11 mediated repression of cPLA2α promoter could be modulated by various signaling-induced post-translational modifications.
Since this data raised the question of whether any of these modifications indeed occur or have a function in vivo, we elected to study phosphorylation of one of these sites, KLF11-by guest on November 19, 2017 http://www.jbc.org/ Downloaded from T56, as a model. This choice was based on computer-assisted predictions showing that KLF11-T56, which lies within the R1 domain adjacent to the Sin3a binding domain, is a target for AKT phosphorylation and our in-silico KLF11 protein analysis suggest that changes in charge and/or structure generated by addition of the phosphate to the threonine may have functional consequences. Moreover, to our knowledge the effect of AKT on cPLA2α, the rate limiting enzyme of PGE2 biosynthesis pathway has not been previously reported. This choice was further supported by the finding that a phosphomimetic mutation at T56 (T to D) results in release of cPLA2α promoter repression by KLF11 but the repression persists with an alanine, nonphosphorylatable, mutation at T56 (EV 1±0.18 and KLF11-WT 0.43±0.06 vs KLF11-T56D 1.2±0.23 and KLF11-T56A 0.42±0.07; FIGURE 5B). This data, together with the fact that the EGFR-AKT pathway plays a significant role in both biology and diseases [56] [57] [58] [59] [60] [61] [62] , led us to investigate whether modulating this signaling cascade alters the phosphorylation of KLF11-T56. To facilitate these studies, we developed a phospho-T56-KLF11 antibody. The specificity of this antibody was confirmed in epithelial cells transfected with either wild type KLF11 or the nonphosphorylatable T56A KLF11 mutant (FIGURE 5C). FLO cells were transfected with KLF11 and treated with either the EGFR inhibitor PD168393 or AKT siRNA in low serum conditions (5% FBS).
After 24-hours, cells were either maintained in low serum or changed to high serum conditions (10% FBS) as a rough method to activate AKT (FIGURE 6S2 and 6S3) . Notably, high serum exposure resulted in increased phosphorylation of T56. More importantly, both, pharmacological and genetic manipulations that inhibit EGFR-AKT decreased the phosphorylation of this site, even in presence of a high serum pulse (FIGURE 5D). Therefore, these experiments demonstrate that KLF11 T56 is phosphorylated by AKT upon EGFR activation.
To define the functional effect of EGFR-AKT signaling on transcriptional repression of cPLA2α via KLF11, we used molecular and pharmacological activation or inhibition of the EGFR-AKT pathway (FIGURE 6 A-D) . FLO cells were co-transfected with cPLA2α along with either EV or KLF11, with or without vErbB or CA-AKT. The results of these experiments demonstrated that while KLF11 alone reduced the cPLA2α promoter activity by 63±4.3%, this repression was markedly antagonized by vErbB and CA-AKT (6±0.9% and 31±7% respectively, p<0.05 compared to KLF11, FIGURE 6A). To further substantiate these results, we co-transfected FLO cells with increasing CA-AKT to KLF11 ratios. Notably, increased CA-AKT released KLF11-dependent repression of the cPLA2α promoter (Supplementary FIGURE 6S1) . Conversely, blockers of the EGFR-AKT pathway (10 μM PD168393, 100 μM LY294002 or 1 μM KP372-1) enhanced KLF11-dependent repression of the cPLA2α promoter by 6-to 8-fold, (p<0.05 compared to blockers alone, FIGURE 6B and 6S2). Complementary studies using the AKT siRNA displayed results similar to the ones obtained using small drug inhibitors (FIGURE 6C and 6S3). In conclusion, both pharmacological and genetic manipulation of EGFR-AKT signaling demonstrated a key role of this pathway in the regulation of KLF11-mediated repression of cPLA2 α.
To define whether the EGFR-AKT pathway directly impacts on the KLF11-mediated regulation of this promoter at the appropriate cis-regulatory site, we repeated these experiments using either the WT or SDM2 mutant cPLA2 α promoter. We find that inhibitors of EGFR-AKT signaling repress the wild type cPLA2α promoter but not the SDM2 mutant (FIGURE 6D). Thus, these results demonstrate that a functional KLF11 binding site is critical for AKT-mediated inhibition of cPLA2α transcription.
Finally, we examined whether EGFR-AKT inhibitors affect KLF11-dependent cPLA2α promoter repression via recruitment of Sin3a, using ChIP assay (FIGURE 6E). These experiments showed that the pharmacological blockers induce an enrichment of Sin3a on the cPLA2 α promoter.
These results were complemented by examining the effect of AKT inhibitors on KLF11-Sin3a complexing. For this purpose, KLF11-transfected FLO cells were treated with either the small drug blockers or AKT siRNA for coimmunoprecipitation studies. Both types of treatments increased the amount of Sin3a associated to KLF11. Thus, AKT inhibition increases the interaction between Sin3a and
DISCUSSION
The current study uncovers important mechanistic insights into novel molecular pathways for the regulation of prostaglandin synthesis by KLF proteins. As evident from the data presented in this study, KLF11 is the first Kruppel like factor family member to be associated with the downregulation of prostaglandin synthesis, particularly PGE2. The transcriptional silencing of cPLA2α, the key regulatory enzyme of PGE2, by KLF11 occurs via binding to distinct cPLA2α promoter elements as well as recruitment of Sin3a-HDAC activity. This activity, required for KLF11-mediated silencing, is antagonized by T56 phosphorylation, which is mediated by the EGFR-AKT pathway. Consequently, these studies reveal previously unknown aspects of the biochemical regulation of prostaglandin biosynthesis at both the transcriptional level by KLF11 and at the level of post-translational changes in the KLF11 protein. Due to the involvement of prostaglandins in a myriad of cellular effects, both, the biological and medical relevance of this information is significant.
While this study focuses on KLF11 mediated regulation of PGE2 synthesis via cPLA2α, interestingly, our own preliminary observations using TRANSFACT (data not shown) predicts that other members of this pathway may also be targets of KLF proteins. This observation could therefore fuel further investigations into the exciting area of research involving the regulation of PGE2 synthesis. A model, as outlined in FIGURE 7, integrates the novel signaling loop described here, which places KLF11 at the center of two novel pathways: the first, a KLF11-Sin3a/HDACcPLA2α pathway that down-regulates the PGE2 synthesis and the second, an EGFR-AKT-KLF11-Sin3a/HDAC-cPLA2α pathway, where EGFR-AKT phosphorylates and functionally inactivates KLF11-mediated repression of cPLA2α. Concretely, KLF11 silences cPLA2α and downregulates PGE2, unless it is antagonized via the EGFR-AKT pathway.
Mechanistically, at transcriptional level, the inhibition of PGE2 pathway occurs via distinct cPLA2α promoter elements, and requires the recruitment of the chromatin remodeling, Sin3a-HDAC complex. Others potential chromatin remodeling protein that could bind to the R2, R3, and zinc finger domains do not appear to be involved in KLF11 mediated cPLA2α promoter repression (FIGURE4). The sequences to which KLF11 binds in the cPLA2α promoter are GC-rich and match the consensus sites previously determined for this protein.
[35] The similarity among the members of the SP/KLF family of proteins to recognize specific GC-rich sequences would predict that other members of this family may also act as regulators of this promoter. Indeed, it has been previously shown that Sp1 binds to the cPLA2α promoter in fibroblast cells from lung, leading to its induction. [63] These observations, when combined with that previously published by our laboratory [34, 64] , postulate at least a minimum "yingyang" mechanism, by which Sp1 would act as an activator, whereas KLF11 as its silencer. Although both, Sp1 and KLF11, are ubiquitously expressed in all the tissues examined (data not shown), it would not be surprising if, similarly, other KLF proteins, with more restricted expression pattern, play a role in regulating prostaglandin biosynthesis, either in different cells or different tissues, and either as activators or repressors in a similar "ying-yang" manner.
This study also reveals an important biochemical finding as it regards to the fine regulation of the KLF11-mediated silencing of cPLA2α. Using a completely unbiased approach involving a combination of bioinformatics and extensive site directed mutagenesis (FIGURE 5), we searched for evidence on the potential regulation of the KLF11-cPLA2α-PGE2 pathway by biochemically important signaling molecules. Surprisingly, this approach revealed that EGFR-AKT pathway mediated phosphorylation of T56 alone can antagonize the repressive function of KLF11. This is a novel and potentially interesting observation since in previous investigations, using heterologous Gal4 proteins and promoter systems, we observed that phosphorylation of all of the 4 existing SXXP sites in KLF11(some of them a slightly further from the R1 domain than T56) by Erk-1 is required to disrupt KLF11-dependent silencing [43] Therefore, together, this data demonstrate that phosphorylation of KLF11 within the region of its interaction with Sin3A is essential for neutralizing the function of KLF11 either by AKT or Erk-1 (T56). However, Erk-1 requires additional sites for achieving the same function than AKT. Furthermore this data also reveals an unexpected yet vital information, that the EGFR can use two different intracellular pathways (Erk2 vs AKT) to achieve the same function, namely inactivation of KLF11.
Even though, the phosphorylation required for KLF11 inactivation by these two pathways target partially the same region, the residues they phosphorylate are not identical. Since the data on the phosphorylation events that can regulate the KLF family members and the functional consequences of these posttranslational effects is scanty, the data from this study certainly contribute to expand our biochemical knowledge about KLF proteins.
Methodologically, our data demonstrates that the candidacy of phosphorylatable residues identified by bioinformatics outnumber the apparent candidates that can disrupt the function of this protein as identified by mutational and functional analysis, at least under basal conditions. This result is consistent with the predictive power of most bioinformatics algorithms. Therefore, based upon our results (bioinformatics vs mutational analysis FIGURE 5), we predict that the existence of additional phosphorylation events, which may regulate R1-mediated repression, will be less likely using this methodology.
Another intriguing biochemical observation to discuss when considering the involvement of KLF11 in the PGE2 synthesis is how this phenomenon has the potential to bring about variations in PGE2 pathway.
The potential variations could result from the existence of several functional KLF11 genetic variants. Some of these variants represent polymorphisms, while others are due to mutations. These genetic variants function differently than their normal counterpart and association studies have already linked these variants to juvenile diabetes. [35] In fact, because these KLF11 variants cause disease, the gene has been recently renamed MODY VII (OMIN: http://www.ncbi.nlm.nih.gov). Of significant importance, these KLF11 genetic variants display variability in their binding to and the regulation of the insulin promoter in part due to the malfunction in their association with Sin3a. Notably, this is the domain that KLF11 uses to repress the cPLA2α promoter and is targeted by EGFR-AKT. Based upon these findings, future studies in our laboratory will seek to define whether potential variations in the regulation of PGE2 biosynthesis result from the existence of different KLF11 polymorphisms thus creating anomalies in the large number of functions associated with this prostaglandin. Therefore, because of the impaired binding of KLF11 variant to Sin3a, the discovery of the mechanisms discussed in this article are of significant biochemical importance.
From the standpoint of cPLA2α-PGE2 pathway regulation, this study offers yet another novel finding. While there is some evidence that AKT-dependent signaling can alter PGE2 synthesis by regulating COX-2 function, our study provides an additional mechanism where AKT, by causing posttranslational changes in KLF11 (P-T56), could alter the transcriptional regulation of cPLA2α.
In conclusion, together, this study significantly expands our understanding of the role of KLF proteins on established and important biochemical pathways, such as prostaglandin biosynthesis. Krüppel-like factors are increasingly being recognized for their ability to govern important biological processes that are involved in mammalian development, differentiation, survival, and aging. [25] [26] [27] . Thus, it is likely that KLFprostaglandin pathways are important regulators of these phenomena.
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Trebino CE, Eskra JD, Wachtmann TS, Perez JR, Carty TJ, Audoly LP: Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. The effect of AACOCF3α on FLO cell proliferation was reversed by the catalytic product of cPLA2α namely arachidonic acid and PGE2. Similar results were noted using other esophageal cancer cells (SKGT-4 and BE-HGD). These findings support that the effect of cPLA2α on cell proliferation is mediated by the release of arachidonic acid and production of PGE2 B-D: Compared to empty vector, adenoviral infection of FLO (MOI 30), SEG-1 (MOI 100) and SKGT-4 (MOI 100) cells for 48 hours with KLF11 significantly (p<0.05) reduced BrdU incorporation in cells that were treated with vehicle (49.5±4.7%, 38.5±1.6% and 40±5.9% respectively for FLO, SEG-1cells and SKGT-4 p<0.05), however this growth inhibitory effect of KLF11 was abrogated in the cells that were treated with 30μM of arachidonic acid (AA, a catalytic product of cPLA2α and substrate of PGE2) or 2 ng/ml PGE2 suggesting that the growth inhibitory effect of KLF11 is mediated via downregulation of cPLA2α-PGE2 pathway. cPLA2α promoter reporter construct. B: Compared to control, KLF11 was able to repress cPLA2α-wt promoter but failed to repress the cPLA2α promoter that had cc to tt mutations in the distal GC-rich site (cPLA2α-wt 36.29±17.7% Vs. cPLA2α-SDM2 80.8±20.9% p<0.05). The mutations in the more proximal GCrich site (SDM1) only partially relived the KLF11-dependent repression (52±14.7%) which was not significantly different compared to cPLA2α-wt. C: EMSA shows that the binding of KLF11-GST recombinant protein and DIG-labeled fragment of cPLA2α core promoter sequence was partially disrupted with SDM-1 mutations (lane 2) and completely disrupted by SDM-2 mutations (lane 3) in GC-rich sequence of the cPLA2α promoter. lane 1 represents the fragments containing wild type cPLA2 α core promoter sequence (Wt-cPLA2 α) and lane 4, 5, and 6 are negative controls. D: ChIP assay using FLO cell lysates shows that the CIS-regulatory cPLA2α promoter sequence is enriched in immunoprecipitated samples from cells infected with KLF11-carrying adenovirus and absent in EV control-infected cells demonstrating that KLF11 can bind to the promoter of cPLA2α endogenously. constructs from a library of mutant KLF11 proteins where serines and threonines were replaced with either alanines or aspartic acids as indicated. The eight phosphomimetic and non-phosphorylatable KLF11 mutants with opposing effect on cPLA2α promoter activity are displayed along with a KLF11 protein domain outline. B: FLO cells co-transfected with the cPLA2α promoter reporter construct along with either empty vector or a phosphomimetic (T56D) or non-phosphorylatable (T56A) KLF11 mutant in the R1 domain (in close proximity of its Sin3a binding site) shows that at 48 hours, compared to control, wild type KLF11 repressed the cPLA2α promoter activity to 43±6% but the phosphomimetic T56D-KLF11 mutant resulted in a complete release of cPLA2α promoter repression by KLF11 (120±23%). The repression of cPLA2α persisted with the T56A-KLF11 mutant (42±7%). C: Lysates from CHO cells transfected with wild type KLF11 or T56A mutant KLF11 after immunoprecipitation of His-tagged KLF11 followed by Western blot with phospho-T56-KLF11 antibody shows the specificity of this antibody as it does not bind to non-phosphorylatable T56A KLF11 D: KLF11 transfected FLO cells were treated with either scrambled siRNA+vehicle or siRNA against AKT (AKT-1, 2 and 3) transfection or PD168393 (EGFR blocker) to inhibit AKT. 24 hours later cell were either maintained in 5% FBS (low serum) or given a 90 minute pulse of high serum media (10% FBS to activate EGFR-AKT pathway). After immunoprecipitating His-tagged KLF11 protein, resolving by 10% SDS-PAGE, and immunoblotting with anti-phospho-T56-KLF11 and total KLF11, as a loading control, we found that the high serum pulse that activates AKT (data shown in supplementary figure 6S2 and 6S3) results in phosphorylation of T56 in KLF11 and that the siRNA against AKT, as well as PD168393 to inhibit AKT, markedly reduced the phosphorylation of this site. (mutation in GC-rich sequence to which KLF11 binds). Cells were treated with either vehicle or 10 μM PD168393 or 100 μM LY294002 or both PD168393 and LY294002 for 24 hours in 10% FBS. PD168393 decreased cPLA2α-wt promoter activity by 66% (100±10% Vs. 44±6% p<0.05) but had no significant effect on the cPLA2α-SDM2 promoter activity (100±33% Vs. 89±35%). Similar pattern was also noted with LY294002 alone or with both PD168393 and LY294002. E: KLF11 transfected FLO cells were treated with either vehicle or 10 μM PD168393 plus 100 μM LY294002 for 24 hours in presence of 10% FBS. chromatin immunoprecipitation with anti-sin3a antibody, showed a slight increase in cPLA2 α promoter enrichment in the blocker treated group. To compliment this, FLO cells were either co-transfected with KLF11 and AKT siRNA (or scramble RNA control) or treated with 10 μM PD168393 plus 100 μM LY294002 (or vehicle control). Western blots after immunoprecipitation of His-tagged KLF11 followed by probing with the antiSin3a antibody shows that compared to control there was increased KLF11-Sin3a complexing in AKT blockers as well as AKTsiRNA treated cells compared to the control. KLF11  S15A  S15D  T19A  T19D  S39A  S39D  T56A  T56D  T90A  T90D  S94A  S94D  S107A  S107D  S149A  S149D  S157A  S157D  T162A  T162D  S181A  S181D  T256A  T256D  S280A  S280D  S362A  S362D  S380A  S380D  T387A  T387D  S392A  S392D  T430A  T430D  T432A  T432D  T461A  T461D  S480A 
